ArticleEnvironmental pollution (Barking, Essex : 1987)2026
Perfluorooctane sulfonate (PFOS) interferes with Cyp1a activity and dysregulates the aryl hydrocarbon receptor pathway in larval zebrafish (Danio rerio).
Article in Environmental pollution (Barking, Essex : 1987), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Per- and poly-fluoroalkyl substances (PFAS) are ubiquitous, persistent toxicants. In the environment, PFAS co-occur with other compounds, including agonists of the aryl hydrocarbon receptor (AHR). In this study, in silico molecular docking, in vitro enzyme activity, and in vivo zebrafish model were used to identify PFAS that may interact with the AHR pathway and assess impacts for developmental toxicity. Of the PFAS and proteins modeled, perfluorooctane sulfonate (PFOS) was predicted in silico by AutoDock Vina to have good affinity for CYP1A1. This prediction was supported by enzyme inhibition assays in vitro, where PFOS inhibited human CYP1A1 (estimated IC50 of 35 μM). For in vivo testing, two PFAS were selected: PFOS and the related perfluorohexane sulfonate (PFHxS), which did not inhibit CYP1A1 activity at tested concentrations in vitro. Zebrafish embryos were exposed from 24 to 100 h post-fertilization to mixtures of PFAS (16 μM) with and without the AHR agonist β-naphthoflavone (βNF; 3.67, 36.7, and 183.6 nM). Co-exposures of βNF and PFOS caused severe morphological deformities not observed with either compound alone, accompanied by reduced Cyp1a-like enzyme activity, and cyp1a gene expression. In contrast, PFHxS did not interfere with Cyp1a activity in vivo and did not cause developmental toxicity. The findings suggest developmental toxicity of mixtures containing PFOS may be underestimated, and identification of other PFAS that interact with the AHR pathway is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.